EGFR and non-small cell lung carcinoma: Furthermore, the high cost of NGS for solid tumors, coupled with the lack of coverage from the National Health Insurance in Taiwan, has historically limited the number of NSCLC patients undergoing EGFR mutation profiling by NGS, thereby restricting concordant comparisons with our in-house method.